Alcon AG (ALC)vsAnbio Biotechnology Class A Ordinary Shares (NNNN)
ALC
Alcon AG
$66.81
+0.35%
HEALTHCARE · Cap: $33.11B
NNNN
Anbio Biotechnology Class A Ordinary Shares
$22.99
-14.88%
HEALTHCARE · Cap: $684.26M
Smart Verdict
WallStSmart Research — data-driven comparison
Alcon AG generates 122882% more annual revenue ($10.63B vs $8.65M). NNNN leads profitability with a 74.1% profit margin vs 7.7%. ALC trades at a lower P/E of 40.7x. NNNN earns a higher WallStSmart Score of 52/100 (C-).
ALC
Hold49
out of 100
Grade: D+
NNNN
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-24.0%
Fair Value
$64.04
Current Price
$66.81
$2.77 premium
Intrinsic value data unavailable for NNNN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Every $100 of equity generates 32 in profit
Keeps 74 of every $100 in revenue as profit
Strong operational efficiency at 59.1%
Revenue surging 73.9% year-over-year
Areas to Watch
Expensive relative to growth rate
ROE of 3.7% — below average capital efficiency
7.7% margin — thin
Weak financial health signals
2.8% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Trading at 33.3x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ALC
The strongest argument for ALC centers on Price/Book, Debt/Equity.
Bull Case : NNNN
The strongest argument for NNNN centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 74.1% and operating margin at 59.1%. Revenue growth of 73.9% demonstrates continued momentum.
Bear Case : ALC
The primary concerns for ALC are PEG Ratio, Return on Equity, Profit Margin. A P/E of 40.7x leaves little room for execution misses.
Bear Case : NNNN
The primary concerns for NNNN are EPS Growth, Market Cap, P/E Ratio. A P/E of 103.9x leaves little room for execution misses.
Key Dynamics to Monitor
ALC profiles as a value stock while NNNN is a growth play — different risk/reward profiles.
NNNN is growing revenue faster at 73.9% — sustainability is the question.
ALC generates stronger free cash flow (274M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NNNN scores higher overall (52/100 vs 49/100), backed by strong 74.1% margins and 73.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alcon AG
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.
Visit Website →Anbio Biotechnology Class A Ordinary Shares
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. The company is headquartered in Frankfurt am Main, Germany.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?